All In Biotech

Drug Trial Radar · NCT06660563

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

A Phase 1b Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers (TCEs) in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoid (R/R B-Cell NHL) Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

19

Actual

Start

Oct 22, 2024

Primary completion

Jan 19, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • JNJ-80948543Drug

    JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.

  • JNJ-75348780Drug

    JNJ-75348780 will be administered as SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-limiting Toxicity (DLT)Time frame: Up to 1 year and 10 months
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to 1 year and 10 months

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Concord Hospital

    Concord, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Australia

  • Macquarie University Hospital

    North Ryde, Australia

  • Hosp Univ Vall D Hebron

    Barcelona, Spain

  • Hosp. Clinic de Barcelona

    Barcelona, Spain

  • Inst. Cat. Doncologia-H Duran I Reynals

    L'Hospitalet de Llobregat, Spain

  • Hosp. Gral. Univ. Gregorio Maranon

    Madrid, Spain

  • Hosp. Univ. 12 de Octubre

    Madrid, Spain

  • China Medical University Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • University Hospitals Of Leicester Nhs Trust

    Leicester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.